非小细胞肺癌EGFR突变检测的研究和应用进展

Research and application progress of detection of EGFR mutation in non-small cell lung cancer

近年来,靶向小分子酪氨酸激酶抑制剂(TKI)在表皮生长因子受体(EGFR)突变的晚期非小细胞肺癌(NSCLC)患者的治疗中得到了广泛应用。对EGFR突变情况进行检测成为晚期NSCLC个体化治疗的重要前提。目前,EGFR突变的检测方法仍以组织检查为金标准,同时,细胞学及外周血EGFR突变检测亦得到良好发展。对EGFR突变水平进行定性及定量测定,可较为方便地预测EGFR-TKI的疗效,监测疾病的进展,并可较早地发现EGFR-TKI获得性耐药。本文对EG-FR突变的定性及定量检测技术的应用进展作一综述。

Recently,targeted drugs are widely used in the treatment of advanced non-small cell lung cancer（NSCLC） patients with EGFR mutation.The detection of EGFR mutation status before treatment becomes important premise of individualized treatment.Now the detection of EGFR mutation mainly uses tissue examination as gold standard.Meanwhile using peripheral blood and cytology to detect EGFR mutation have been well developed.The qualitative and quantitative detection of EGFR mutations would be useful for predicting treatment response,monitoring disease progression and early detection of treatment failure associated with acquired drug resistance.